Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients
References (11)
- et al.
The mechanism of action of FK-506 and cyclosporin A
Ann New York Acad Sci
(1994) Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
Lancet
(1994)- et al.
Management of intestinal transplantation in humans
Transplant Proc
(1992) - et al.
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy: a clinicopathologic study of 96 patients
Transplantation
(1992) - et al.
The effects of FK506 on renal function after liver transplantation
Transplant Proc
(1990)
Cited by (176)
What Causes Hypertrophic Cardiomyopathy?
2022, American Journal of CardiologyDilated Cardiomyopathy in an Adult Renal Transplant Recipient: Recovery Upon Tacrolimus to Sirolimus Switch: A Case Report
2020, Transplantation ProceedingsCitation Excerpt :It has adverse renal, central nervous system, and vascular side effects that have been previously documented. The cardiotoxic effects of tacrolimus are uncommon and have been most commonly characterized as obstructive or concentric hypertrophic cardiomyopathy described following liver, bowel, renal, and heart transplants [2,3,5]. McLeod et al described development of cardiac hypertrophy shortly after the introduction of tacrolimus, particularly involving the intraventricular septum, which then rapidly progressed to a dilated cardiomyopathy [4].
Oral administration of Lactococcus chungangensis inhibits 2,4-dinitrochlorobenzene-induced atopic-like dermatitis in NC/Nga mice
2016, Journal of Dairy ScienceCitation Excerpt :Tacrolimus exerts its therapeutic effect by inhibiting the production of proinflammatory cytokines (Nasr, 2000; Reitamo et al., 2000). In addition, tacrolimus has been reported to cause side effects such as headache, paresthesia, tremor, tinnitus, photophobia, blurred vision, gastrointestinal upset, nausea, vomiting, hyperkalemia, hypertension, and hyperuricemia (Atkison et al., 1995). This highlights the urgent need to develop new therapies that target the underlying causes of AD.
De novo aortopathy and cardiovascular outcomes in paediatric liver transplant recipients
2018, Cardiology in the YoungGet to the heart of pediatric kidney transplant recipients: Evaluation of left- and right ventricular mechanics by three-dimensional echocardiography
2023, Frontiers in Cardiovascular MedicineThe effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice
2022, BMC Pharmacology and Toxicology